Literature DB >> 26690656

Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients.

Francesca Bedussi1,2, Francesca Valcamonico3, Alessandra Mosca4, Sandra Sigala2, Laura Ferrari1, Carlo Terrone5, Alberto Dalla Volta1, Giansilvio Marchioro5, Vittorio Ferrari1, Oscar Alabiso4, Maurizio Memo2, Alfredo Berruti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26690656     DOI： 10.1007/s12020-015-0827-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  18 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 2.  Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.

Authors:  William P Harris; Elahe A Mostaghel; Peter S Nelson; Bruce Montgomery
Journal:  Nat Clin Pract Urol       Date:  2009-02

3.  Testosterone serum levels and prostate cancer prognosis: the double face of Janus.

Authors:  Francesca Valcamonico; Laura Ferrari; Francesca Consoli; Vito Amoroso; Alfredo Berruti
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Authors:  Medha S Darshan; Matthew S Loftus; Maria Thadani-Mulero; Benjamin P Levy; Daniel Escuin; Xi Kathy Zhou; Ada Gjyrezi; Chantal Chanel-Vos; Ruoqian Shen; Scott T Tagawa; Neil H Bander; David M Nanus; Paraskevi Giannakakou
Journal:  Cancer Res       Date:  2011-07-28       Impact factor: 12.701

6.  Importance of continued testicular suppression in hormone-refractory prostate cancer.

Authors:  C D Taylor; P Elson; D L Trump
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.

Authors:  Paul Thelen; Elmar Heinrich; Felix Bremmer; Lutz Trojan; Arne Strauss
Journal:  Prostate       Date:  2013-07-19       Impact factor: 4.104

Review 9.  Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Authors:  Ethan Basch; D Andrew Loblaw; Thomas K Oliver; Michael Carducci; Ronald C Chen; James N Frame; Kristina Garrels; Sebastien Hotte; Michael W Kattan; Derek Raghavan; Fred Saad; Mary-Ellen Taplin; Cindy Walker-Dilks; James Williams; Eric Winquist; Charles L Bennett; Ted Wootton; R Bryan Rumble; Stacie B Dusetzina; Katherine S Virgo
Journal:  J Clin Oncol       Date:  2014-09-08       Impact factor: 44.544

10.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544
View more
  1 in total

1.  Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.

Authors:  Irene Caramella; Alberto Dalla Volta; Marco Bergamini; Deborah Cosentini; Francesca Valcamonico; Alfredo Berruti
Journal:  Endocrine       Date:  2022-08-20       Impact factor: 3.925
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.